Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Achondroplasia
- Main trialPhase 3
- “This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia”In the company’s words, NCT06926491 on ClinicalTrials.gov
Other drugs for Achondroplasia
- NavepegritideAscendis Pharma A/S · Phase 3
- VosoritideBioMarin Pharmaceutical · Phase 3
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- BMN 333BioMarin Pharmaceutical · Phase 2/3
- ABSK061Abbisko Therapeutics Co, Ltd · Phase 1/2
- DabogratinibTyra Biosciences, Inc · Phase 2
Coming up1
- 31 May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 May 2029 | Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026